Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 8/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.40 |
| ▸ | GRK6 | P43250 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22700704 | 0.88 | MCL1 (0.46) | BCL2MCL1GRK6MEN1KMT2A | |
| SCHEMBL22700390 | 0.85 | MCL1 (0.50) | BCL2MCL1MEN1KMT2A | |
| SCHEMBL22700775 | 0.83 | MAOA (0.36) | BCL2MCL1MEN1KMT2AHSD17B10 | |
| SCHEMBL22686504 | 0.81 | ALB (0.42) | BCL2MCL1MEN1KMT2AHSD17B10 | |
| SCHEMBL22700400 | 0.80 | MAPT (0.36) | BCL2MCL1MEN1KMT2A | |
| SCHEMBL22700765 | 0.78 | SMN1; SMN2 (0.32) | KMT2A | |
| SCHEMBL22700774 | 0.78 | CNR2 (0.34) | HSD17B10CNR2 | |
| SCHEMBL22700720 | 0.77 | MAPT (0.42) | BCL2MCL1MEN1KMT2A | |
| SCHEMBL1890983 | 0.77 | EGFR (0.42) | BCL2MCL1MEN1KMT2AHSD17B10 | |
| SCHEMBL22700398 | 0.75 | MEN1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | Nearmedic International Limited (CY) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | DNM2, DNM1, MAVS | BCL2 3675/4885MCL1 3671/4885GRK6 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.